<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medalphabet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский алфавит</journal-title><trans-title-group xml:lang="en"><trans-title>Medical alphabet</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2078-5631</issn><issn pub-type="epub">2949-2807</issn><publisher><publisher-name>ООО «Альфмед»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.33667/2078-5631-2024-29-68-74</article-id><article-id custom-type="elpub" pub-id-type="custom">medalphabet-4051</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group></article-categories><title-group><article-title>Основные про- и антивоспалительные цитокины при ревматоидном артрите: взаимосвязи и патогенетическое значение</article-title><trans-title-group xml:lang="en"><trans-title>The main pro- and antiinflammatory cytokines in rheumatoid arthritis: interrelationships and pathogenetic significance</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2692-399X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лапкина</surname><given-names>Н. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Lapkina</surname><given-names>N. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Наталья Александровна Лапкина, к. м. н., доцент</p><p>кафедра поликлинической терапии, клинической лабораторной диагностики и медицинской биохимии</p><p>Ярославль</p></bio><bio xml:lang="en"><p>Natalia A. Lapkina,  PhD Med, associate professor</p><p>Dept Polyclinic Therapy, Clinical Laboratory Diagnostics and Medical Biochemistry</p><p>Yaroslavl</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7847-1679</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Баранов</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Baranov</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Андрей Анатольевич Баранов, д. м. н., проф., зав. кафедрой</p><p>кафедра поликлинической терапии, клинической лабораторной диагностики и медицинской биохимии</p><p>Ярославль</p></bio><bio xml:lang="en"><p>Andrey A. Baranov, DM Sci (habil.), professor, head at Dept</p><p>Dept Polyclinic Therapy, Clinical Laboratory Diagnostics and Medical Biochemistry</p><p>Yaroslavl</p></bio><email xlink:type="simple">bara_aa@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8557-7372</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Воронцова</surname><given-names>И. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Vorontsova</surname><given-names>I. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Инесса Михайловна Воронцова, к. м. н., доцент</p><p>кафедра поликлинической терапии, клинической лабораторной диагностики и медицинской биохимии</p><p>Ярославль</p></bio><bio xml:lang="en"><p>Inessa M. Vorontsova, PhD Med, associate professor</p><p>Dept Polyclinic Therapy, Clinical Laboratory Diagnostics and Medical Biochemistry</p><p>Yaroslavl</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0000-6641-7544</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Коновалов</surname><given-names>К. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Konovalov</surname><given-names>K. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кирилл Михайлович Коновалов, аспирант</p><p>кафедра поликлинической терапии, клинической лабораторной диагностики и медицинской биохимии</p><p>Ярославль</p></bio><bio xml:lang="en"><p>Kirill M. Konovalov, Postgraduate student</p><p>Dept Polyclinic Therapy, Clinical Laboratory Diagnostics and Medical Biochemistry</p><p>Yaroslavl</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7969-6538</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Чижов</surname><given-names>П. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Chizhov</surname><given-names>P. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Петр Александрович Чижов, д. м. н., проф., зав. кафедрой</p><p>кафедра факультетской терапии</p><p>Ярославль</p></bio><bio xml:lang="en"><p>Petr A. Chizhov, DM Sci (habil.), professor, head at Department</p><p>Department of Faculty Therapy</p><p>Yaroslavl</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0007-1753-0752</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лебедев</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Lebedev</surname><given-names>O. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Олег Владимирович Лебедев, к. м. н., зав. кафедрой, заместитель главного врача по медицинской части</p><p>базовая кафедра в г. Кострома</p><p>Ярославль; Кострома</p></bio><bio xml:lang="en"><p>Oleg V. Lebedev, PhD Med, head at Dept, Deputy Chief Physician for Medical Part</p><p>Base Dept in Kostroma</p><p>Yaroslavl; Kostroma</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2487-5760</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Буйдина</surname><given-names>Т. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Buydina</surname><given-names>T. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Татьяна Алексеевна Буйдина, к. м. н., доцент</p><p>кафедра поликлинической терапии, клинической лабораторной диагностики и медицинской биохимии</p><p>Ярославль</p></bio><bio xml:lang="en"><p>Tatyana A. Buydina, PhD Med, associate professor</p><p>Dept Polyclinic Therapy, Clinical Laboratory Diagnostics and Medical Biochemistry</p><p>Yaroslavl</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Ярославский государственный медицинский университет» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Yaroslavl State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБОУ ВО «Ярославский государственный медицинский университет» Минздрава России; ОГБУЗ «Костромская областная клиническая больница имени Е. И. Королева» Департамента здравоохранения Костромской области</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Yaroslavl State Medical University; Kostroma Regional Clinical Hospital named after E. I. Korolev</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>12</day><month>12</month><year>2024</year></pub-date><volume>0</volume><issue>29</issue><issue-title>Ревматология в общей врачебной практике (2)</issue-title><fpage>68</fpage><lpage>74</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Лапкина Н.А., Баранов А.А., Воронцова И.М., Коновалов К.М., Чижов П.А., Лебедев О.В., Буйдина Т.А., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Лапкина Н.А., Баранов А.А., Воронцова И.М., Коновалов К.М., Чижов П.А., Лебедев О.В., Буйдина Т.А.</copyright-holder><copyright-holder xml:lang="en">Lapkina N.A., Baranov A.A., Vorontsova I.M., Konovalov K.M., Chizhov P.A., Lebedev O.V., Buydina T.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-alphabet.com/jour/article/view/4051">https://www.med-alphabet.com/jour/article/view/4051</self-uri><abstract><p>   В патогенезе ревматоидного артрита (РА) важную роль играет дисбаланс продукции про- и антивоспалительных цитокинов.</p><sec><title>   Цель исследования</title><p>   Цель исследования. Определение у больных РА в развернутой стадии заболевания концентрации и частоты повышения в сыворотке крови про- и антивоспалительных цитокинов, оценка взаимосвязи между ними, клинико-лабораторной активностью заболевания и аутоантителами.</p></sec><sec><title>   Материалы и методы</title><p>   Материалы и методы. Обследовано 154 больных РА (41 мужчина и 113 женщин) среднего возраста (56,0 [50,0; 64,0] лет), длительностью заболевания (9,4 [3,0; 13,0] года), серопозитивных 129 (83,8 %) по IgM ревматоидному фактору (РФ) и/или 106 (68,8 %) антителам к циклическим цитруллинированным пептидам (АЦЦП) с умеренной или высокой (DAS 28-СОЭ – 5,40 [4,65; 6,00]) активностью заболевания. Определяли в сыворотке крови концентрацию интерлейкинов (ИЛ), фактора некроза опухоли α (ФНО-α), интерферона-γ (ИНФ-γ) и растворимого CD 40 лиганда (sCD 40L) мультиплексной технологией.</p></sec><sec><title>   Результаты</title><p>   Результаты. У больных РА концентрация ИЛ-6, ИЛ-23, ИЛ-31, ИЛ-33 и ИНФ-γ была достоверно выше, а значения ФНО-α – значимо ниже, чем в контроле. Уровни ИЛ-1β, ИЛ-17A, ИЛ-17F, ИЛ-25 и sCD 40L не отличались от доноров. Значения ИЛ-10 были достоверно выше, чем у доноров, а ИЛ-4 не имели различий с контролем. При РА частота повышения ИЛ-33 составила 87,0 %, ИЛ-6 – 51,6 %, ИЛ-31 – 48,1 %, ИЛ-17F – 46,1 %, ИЛ-23 – 42,9 % и ИНФ-γ – 39,0 %, ИЛ-17A – 29,9 %, ИЛ-1β – 26,6 %, ФНО-α – 23,4 %, ИЛ-25 – 11,7 % и sCD 40L 3,2 % больных. Гиперпродукция ИЛ-33 достоверно преобладала над другими цитокинами (p &lt; 0,001). Повышенные значения ИЛ-10 выявлены у 16,2 %, а ИЛ-4 – у 12,3 % больных. Гиперпродукция провоспалительных цитокинов, кроме ИЛ-25 и sCD 40L, достоверно превалировала над ИЛ-4 и ИЛ-10. Выявлены корреляции провоспалительных цитокинов между собой и с ИЛ-4 и ИЛ-10. Высокие значения ИЛ-33 ассоциировались только с ИЛ-31. Концентрации ИЛ-4 и ИЛ-10 достоверно коррелировали между собой. Установлены связи концентрации ИЛ-6 с DAS 28-СОЭ, CDAI и SDAI; ИЛ-25 и sCD 40L – с CDAI и SDAI; ИЛ-17A и ИЛ-33 – с SDAI; ИЛ-4 и ИЛ-10 – с CDAI и SDAI; ИЛ-31 и ИЛ-33 – с СРБ; ФНО-α и ИНФ-γ – с СОЭ; ИЛ-17A – и IgM РФ и АЦЦП; ИЛ-31 и ИНФ-γ – с IgM РФ. ИЛ-4 и ИЛ-10 положительно коррелировали с IgM РФ, а ИЛ-4 – отрицательно с АЦЦП.</p></sec><sec><title>   Выводы</title><p>   Выводы. У больных РА в развернутую стадию заболевания наблюдается дисбаланс продукции про- и антивоспалительных цитокинов с преобладанием выработки ИЛ-33. Несмотря на наличие тесных взаимосвязей между цитокинами, имеют место существенные различия между ними в ассоциациях с клиническими индексами, лабораторными показателями активности болезни и аутоантителами.</p></sec></abstract><trans-abstract xml:lang="en"><p>   Imbalance in the production of pro- and anti-inflammatory cytokines plays an important role in the pathogenesis of rheumatoid arthritis (RA).</p><sec><title>  The aim of the study</title><p>  The aim of the study. To determine the concentration and frequency of increase in serum of pro- and anti-inflammatory cytokines in patients with RA in the advanced stage of the disease, assessment of the relationship between them, clinical and laboratory activity of the disease and autoantibodies.</p></sec><sec><title>   Materials and methods</title><p>   Materials and methods. We examined 154 RA patients (41 men and 113) women, of average age (56.0 [50.0; 64.0] years), disease duration (9.4 [3.0; 13.0] years), seropositive 129 (83.8 %) for IgM rheumatoid factor (RF) and/or 106 (68.8 %) antibodies to cyclic citrullinated peptides (ACCP) with moderate to high (DAS 28-ESR – 5.40 [4.65; 6.00]) disease activity. The concentration of interleukin (IL), tumor necrosis factor α (TNF-α), interferon-γ (INF-γ), soluble CD 40 ligand (sCD 40L) in serum was determined by multiplex technology.</p></sec><sec><title>   Results</title><p>   Results. In RA patients, the concentration of IL-6, IL-23, IL-31, IL-33 and INF-γ was significantly higher, and TNF-α values were significantly lower than in controls. The levels of IL-1β, IL-17A, IL-17F, IL-25 and sCD 40L were not different from donors. IL-10 values were significantly higher than donors, and IL-4 values were not different from controls. In RA, the frequency of IL-33 elevation was 87.0 %, IL-6 51.6 %, IL-31 48.1 %, IL-17F 46.1 %, IL-23 42.9 % and INF-γ 39.0 %, IL-17A 29.9 %, IL-1β 26.6 %, TNF-α 23.4 %, IL-25 11.7 % and sCD 40L 3.2 % of patients. IL-33 hyperproduction was significantly predominant over other cytokines (p &lt; 0.001). Elevated values of IL-10 were found in 16.2 % and IL-4 in 12.3 % of patients. Hyperproduction of proinflammatory cytokines, except IL-25 and sCD 40L, significantly prevailed over IL-4 and IL-10. Correlations of proinflammatory cytokines among themselves and with IL-4 and IL-10 were found. High values of IL-33 were associated only with IL-31. IL-4 and IL-10 concentrations were significantly correlated with each other. IL-6 concentration was found to be associated with DAS 28-ESR, CDAI and SDAI; IL-25 and sCD 40L were associated with CDAI and SDAI; IL-17A and IL-33 were associated with SDAI; IL-4 and IL-10, with CDAI and SDAI; IL-31 and IL-33, with CRP; TNF-α and INF-γ, with CRP; IL-17A, and IgM RF and ACCP; IL-31 and INF-γ, with IgM RF. IL-4 and IL10 were positively correlated with IgM RF, and IL-4 was negatively correlated with ADCP.</p></sec><sec><title>   Conclusions</title><p>   Conclusions. In RA patients in the advanced stage of the disease, there is an imbalance between pro- and anti-inflammatory cytokines, with a predominance of IL-33 production. Despite the presence of interrelationships between cytokines, there are significant differences between them in associations with clinical indices, laboratory indicators of disease activity and autoantibodies.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>ревматоидный артрит</kwd><kwd>цитокины</kwd><kwd>интерлейкин 33</kwd><kwd>активность заболевания</kwd></kwd-group><kwd-group xml:lang="en"><kwd>rheumatoid arthritis</kwd><kwd>cytokines</kwd><kwd>interleukin 33</kwd><kwd>disease activity</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Исследование не имело спонсорской поддержки</funding-statement><funding-statement xml:lang="en">The study had no sponsorship</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016; 388 (10055): 2023–2038. DOI: 10.1016/S 0140-6736 (16) 30173-8</mixed-citation><mixed-citation xml:lang="en">Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016; 388 (10055): 2023–2038. DOI: 10.1016/S 0140-6736 (16) 30173-8</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов Е. Л. Современная концепция аутоиммунитета в ревматологии. Научно-практическая ревматология. 2023; 61 (4): 397–420. DOI: 10.47360/1995-4484-2023-397-420</mixed-citation><mixed-citation xml:lang="en">Nasonov E. L. Modern concept of autoimmunity in rheumatology. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2023; 61 (4): 397–420. (In Russ.). DOI: 10.47360/1995-4484-2023-397-420</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Gao Y, Zhang Y, Liu X. Rheumatoid arthritis: pathogenesis and therapeutic advances. MedComm. 2024; 5 (3): e509. DOI: 10.1002/mco2.509</mixed-citation><mixed-citation xml:lang="en">Gao Y, Zhang Y, Liu X. Rheumatoid arthritis: pathogenesis and therapeutic advances. MedComm. 2024; 5 (3): e509. DOI: 10.1002/mco2.509</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Sivalingam SP, Thumboo J, Vasoo S, Thio ST, Tse C, Fong KY. In vivo pro- and anti-inflammatory cytokines in normal and patients with rheumatoid arthritis. Ann Acad Med Singap. 2007; 36 (2): 96–9.</mixed-citation><mixed-citation xml:lang="en">Sivalingam SP, Thumboo J, Vasoo S, Thio ST, Tse C, Fong KY. In vivo pro- and anti-inflammatory cytokines in normal and patients with rheumatoid arthritis. Ann Acad Med Singap. 2007; 36 (2): 96–9.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Новиков А. А., Александрова Е. Н., Герасимова А. Н., Черкасова М. В., Каратеев Д. Е. и соавт. Многопараметрический анализ биомаркеров в лабораторной диагностике раннего ревматоидного артрита. Научно-практическая ревматология. 2013; 51 (2): 111–116. DOI: 10.14412/1995-4484-2013-636</mixed-citation><mixed-citation xml:lang="en">Novikov A. A., Aleksandrova E. N., Gerasimova A. N., Cherkasova M. V., Karateev D. E. et al. Multiparameter analysis of biomarkers in the laboratory diagnosis of early rheumatoid arthritis. Rheumatology Science and Practice. 2013; 51 (2): 111–116. (In Russ.). DOI: 10.14412/1995-4484-2013-636</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Ridgley LA, Anderson AE, Pratt AG. What are the dominant cytokines in early rheumatoid arthritis? Curr Opin Rheumatol. 2018; 30 (2): 207–214. DOI: 10.1097/BOR.0000000000000470</mixed-citation><mixed-citation xml:lang="en">Ridgley LA, Anderson AE, Pratt AG. What are the dominant cytokines in early rheumatoid arthritis? Curr Opin Rheumatol. 2018; 30 (2): 207–214. DOI: 10.1097/BOR.0000000000000470</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Новиков А. А., Александрова Е. Н., Лукина Г. В. Особенности цитокинового профиля при ревматоидном артрите. Альманах клинической медицины. . 2019; 47 (5): 393–9. DOI: 10.18786/2072-0505-2019-47-058</mixed-citation><mixed-citation xml:lang="en">Novikov A. A., Aleksandrova E. N., Lukina G. V. Serum cytokine profile in early and established rheumatoid arthritis. Almanac of Clinical Medicine. 2019; 47 (5): 393–9. (In Russ.). DOI: 10.18786/2072-0505-2019-47-058</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Livshits G, Kalinkovich A. Hierarchical, imbalanced pro-inflammatory cytokine networks govern the pathogenesis of chronic arthropathies. Osteoarthritis Cartilage. 2018; 26 (1): 7–17. DOI: 10.1016/j.joca.2017.10.013</mixed-citation><mixed-citation xml:lang="en">Livshits G, Kalinkovich A. Hierarchical, imbalanced pro-inflammatory cytokine networks govern the pathogenesis of chronic arthropathies. Osteoarthritis Cartilage. 2018; 26 (1): 7–17. DOI: 10.1016/j.joca.2017.10.013</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Liu R, Wang F, Luo X, Yang F, Gao J. et al. The immunomodulatory of interleukin-33 in rheumatoid arthritis : A systematic review. Clin Immunol. 2024; 265: 110264. DOI: 10.1016/j.clim.2024.110264</mixed-citation><mixed-citation xml:lang="en">Liu R, Wang F, Luo X, Yang F, Gao J. et al. The immunomodulatory of interleukin-33 in rheumatoid arthritis : A systematic review. Clin Immunol. 2024; 265: 110264. DOI: 10.1016/j.clim.2024.110264</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Cicuttini FM, Byron KA, Maher D, Wootton AM, Muirden KD, Hamilton JA. Serum IL-4, IL-10 and IL-6 levels in inflammatory arthritis. Rheumatol Int. 1995; 14 (5): 201–6. DOI: 10.1007/BF00262298</mixed-citation><mixed-citation xml:lang="en">Cicuttini FM, Byron KA, Maher D, Wootton AM, Muirden KD, Hamilton JA. Serum IL-4, IL-10 and IL-6 levels in inflammatory arthritis. Rheumatol Int. 1995; 14 (5): 201–6. DOI: 10.1007/BF00262298</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Saxena A, Khosraviani S, Noel S, Mohan D, Donner T, Hamad AR. Interleukin-10 paradox: A potent immunoregulatory cytokine that has been difficult to harness for immunotherapy. Cytokine. 2015 Jul; 74 (1): 27–34. DOI: 10.1016/j.cyto.2014.10.031</mixed-citation><mixed-citation xml:lang="en">Saxena A, Khosraviani S, Noel S, Mohan D, Donner T, Hamad AR. Interleukin-10 paradox: A potent immunoregulatory cytokine that has been difficult to harness for immunotherapy. Cytokine. 2015 Jul; 74 (1): 27–34. DOI: 10.1016/j.cyto.2014.10.031</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Iwaszko M, Biały S, Bogunia-Kubik K. Significance of Interleukin (IL)-4 and IL-13 in Inflammatory Arthritis. Cells. 2021 Nov 3; 10 (11): 3000. DOI: 10.3390/cells10113000</mixed-citation><mixed-citation xml:lang="en">Iwaszko M, Biały S, Bogunia-Kubik K. Significance of Interleukin (IL)-4 and IL-13 in Inflammatory Arthritis. Cells. 2021 Nov 3; 10 (11): 3000. DOI: 10.3390/cells10113000</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Лапкина Н. А., Баранов А. А., Абайтова Н. Е., Левшин Н. Ю., Речкина О. П. и соавт. ИЛ-31 и ИЛ-33 у больных ревматоидным артритом. Научно-практическая ревматология. 2022; 60 (5): 554–559. DOI: 10.47360/1995-4484-2022-554-559</mixed-citation><mixed-citation xml:lang="en">Lapkina N. A., Baranov A. A., Abaytova N. E., Levshin N. Yu., Rechkina O. P. et al. IL-31 and IL-33 in rheumatoid arthritis patients. Nauchno-Prakticheskaya Revmatologia = Rheu matology Science and Practice. 2022; 60 (5): 554–559. (In Russ.). DOI: 10.47360/1995-4484-2022-554-559</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Лапкина Н. А., Баранов А. А., Речкина О. П., Абайтова Н. Е., Золотавкина С. С. и соавт. ИЛ-17А, ИЛ-17F и ИЛ-23 у больных ревматоидным артритом. Научно-практическая ревматология. 2024; 62 (4): 402–407. DOI: 10.47360/1995-4484-2024-402-407</mixed-citation><mixed-citation xml:lang="en">Lapkina N. A., Baranov A. A., Rechkina O. P., Abaytova N. E., Zolotavkina S. S., et al. IL-17A, IL-17F and IL-23 in patients with rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2024; 62 (4): 402–407. (In Russ.). DOI: 10.47360/1995-4484-2024-402-407</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Reyes-Castillo Z, Palafox-Sánchez CA, Parra-Rojas I, Martínez-Bonilla GE, del Toro-Arreola S, Ramírez-Dueñas MG, Ocampo-Bermudes G, Muñoz-Valle JF. Comparative analysis of autoantibodies targeting peptidylarginine deiminase type 4, mutated citrullinated vimentin and cyclic citrullinated peptides in rheumatoid arthritis: associations with cytokine profiles, clinical and genetic features. Clin Exp Immunol. 2015; 182 (2): 119–31. DOI: 10.1111/cei.12677</mixed-citation><mixed-citation xml:lang="en">Reyes-Castillo Z, Palafox-Sánchez CA, Parra-Rojas I, Martínez-Bonilla GE, del Toro-Arreola S, Ramírez-Dueñas MG, Ocampo-Bermudes G, Muñoz-Valle JF. Comparative analysis of autoantibodies targeting peptidylarginine deiminase type 4, mutated citrullinated vimentin and cyclic citrullinated peptides in rheumatoid arthritis: associations with cytokine profiles, clinical and genetic features. Clin Exp Immunol. 2015; 182 (2): 119–31. DOI: 10.1111/cei.12677</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов Е. Л. Проблемы иммунопатологии ревматоидного артрита: эволюция болезни. Научно-практическая ревматология. 2017; 55 (3): 277–294. DOI: 10.14412/1995-4484-2017-277-294</mixed-citation><mixed-citation xml:lang="en">Nasonov E. L. Problems of rheumatoid arthritis immunopathology: Evolution of the disease. Nauchno Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017; 55 (3): 277–294. (In Russ.). DOI: 10.14412/1995-4484-2017-277-294</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet. 2017; 389 (10086): 2328–2337. DOI: 10.1016/S0140-6736(17)31472-1</mixed-citation><mixed-citation xml:lang="en">McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet. 2017; 389 (10086): 2328–2337. DOI: 10.1016/S0140-6736(17)31472-1</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Hitchon CA, Alex P, Erdile LB, Frank MB, Dozmorov I. et al. A distinct multicytokine profile is associated with anti-cyclical citrullinated peptide antibodies in patients with early untreated inflammatory arthritis. J. Rheumatol. 2004; 31 (12): 2336–46.</mixed-citation><mixed-citation xml:lang="en">Hitchon CA, Alex P, Erdile LB, Frank MB, Dozmorov I. et al. A distinct multicytokine profile is associated with anti-cyclical citrullinated peptide antibodies in patients with early untreated inflammatory arthritis. J. Rheumatol. 2004; 31 (12): 2336–46.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Meyer PW, Hodkinson B, Ally M, Musenge E, Wadee AA. et al. Circulating cytokine profiles and their relationships with autoantibodies, acute phase reactants, and disease activity in patients with rheumatoid arthritis. Mediators Inflamm. 2010; 2010: 158514. DOI: 10.1155/2010/158514</mixed-citation><mixed-citation xml:lang="en">Meyer PW, Hodkinson B, Ally M, Musenge E, Wadee AA. et al. Circulating cytokine profiles and their relationships with autoantibodies, acute phase reactants, and disease activity in patients with rheumatoid arthritis. Mediators Inflamm. 2010; 2010: 158514. DOI: 10.1155/2010/158514</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Новиков A. A., Александрова Е. Н., Герасимова А. Н., Каратеев Д. E., Попкова Т. В. и соавт. Применение многопараметрического анализа лабораторных биомаркеров для оценки активности ревматоидного артрита. Научно-практическая ревматология. 2015; 53 (6): 591–5. DOI: 10.14412/1995-4484-2015-591-595</mixed-citation><mixed-citation xml:lang="en">Novikov A. A., Aleksandrova E. N., Gerasimova A. N., Karateev D. E., Popkova T. V. et al. Use of multiparameter analysis of laboratory biomarkers to assess rheumatoid arthritis activity. Nauchno-Prakticheskaya Revmatologiya=Rheumatology Science and Practice. 2015; 53 (6): 591–5. (In Russ.). DOI: 10.14412/1995-4484-2015-591-595</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Heine G, Drozdenko G, Grün JR, Chang HD, Radbruch A. et al. Autocrine IL-10 promotes human B-cell differentiation into IgM- or IgG-secreting plasmablasts. Eur. J. Immunol. 2014; 44 (6): 1615–21. DOI: 10.1002/eji.201343822</mixed-citation><mixed-citation xml:lang="en">Heine G, Drozdenko G, Grün JR, Chang HD, Radbruch A. et al. Autocrine IL-10 promotes human B-cell differentiation into IgM- or IgG-secreting plasmablasts. Eur. J. Immunol. 2014; 44 (6): 1615–21. DOI: 10.1002/eji.201343822</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Banchereau J. Converging and diverging properties of human interleukin-4 and interleukin-10. Behring Inst Mitt. 1995; 96: 58–77.</mixed-citation><mixed-citation xml:lang="en">Banchereau J. Converging and diverging properties of human interleukin-4 and interleukin-10. Behring Inst Mitt. 1995; 96: 58–77.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Danieli MG, Antonelli E, Piga MA, Claudi I, Palmeri D, Tonacci A, Allegra A, Gangemi S. Alarmins in autoimmune diseases. Autoimmun Rev. 2022 Sep; 21 (9): 103142. DOI: 10.1016/j.autrev.2022.103142</mixed-citation><mixed-citation xml:lang="en">Danieli MG, Antonelli E, Piga MA, Claudi I, Palmeri D, Tonacci A, Allegra A, Gangemi S. Alarmins in autoimmune diseases. Autoimmun Rev. 2022 Sep; 21 (9): 103142. DOI: 10.1016/j.autrev.2022.103142</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Баглай Е. О., Дубиков А. И. Тучные клетки – ключевые участники патогенеза иммуновоспалительных заболеваний. Научно-практическая ревматология. 2015; 53 (2): 182–189. DOI: 10.14412/1995-4484-2015-182-189</mixed-citation><mixed-citation xml:lang="en">Baglay E. O., Dubikov A. I. Mast cells are key participants in the pathogenesis of immunoinflammatory diseases. Rheumatology Science and Practice. 2015; 53 (2): 182–189. (In Russ.). DOI: 10.14412/1995-4484-2015-182-189</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Kiełbowski K, Stańska W, Bakinowska E, Rusiński M, Pawlik A. The role of alarmins in the pathogenesis of rheumatoid arthritis, osteoarthritis, and psoriasis. Curr Issues Mol Biol. 2024; 46 (4): 3640–3675. DOI: 10.3390/cimb46040228</mixed-citation><mixed-citation xml:lang="en">Kiełbowski K, Stańska W, Bakinowska E, Rusiński M, Pawlik A. The role of alarmins in the pathogenesis of rheumatoid arthritis, osteoarthritis, and psoriasis. Curr Issues Mol Biol. 2024; 46 (4): 3640–3675. DOI: 10.3390/cimb46040228</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Rahmati M, Kwesiga MP, Lou J, Tan AL, McDermott MF. Novel Targeted Therapies for Rheumatoid Arthritis Based on Intracellular Signalling and Immunometabolic Changes : A Narrative Review. Front Biosci (Landmark Ed). 2024; 29 (1): 42. DOI: 10.31083/j.fbl2901042</mixed-citation><mixed-citation xml:lang="en">Rahmati M, Kwesiga MP, Lou J, Tan AL, McDermott MF. Novel Targeted Therapies for Rheumatoid Arthritis Based on Intracellular Signalling and Immunometabolic Changes : A Narrative Review. Front Biosci (Landmark Ed). 2024; 29 (1): 42. DOI: 10.31083/j.fbl2901042</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
